-葡萄糖共运输体2 代谢功能障碍与相关的脂肪肝炎的抑制剂
Jiayang Lin1, Yan Huang2, Bingyan Xu1
1Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Journal of diabetes
|March 7, 2026
概括
代谢功能障碍相关的脂肪肝炎 (MASH) 的改善需要NAS得分显著下降或≤3,有稳定的纤维化. MASH的解决方案涉及最小的气球和炎症,并没有纤维化恶化.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 代谢疾病 代谢疾病
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种进展性肝病.
- 对MASH结果的准确定义对于临床试验和患者管理至关重要.
研究的目的:
- 确定MASH改善,解决和纤维化改善的客观标准.
- 建立MASH临床研究的标准化终点.
主要方法:
- 根据非酒精性脂肪性肝病活动评分 (NAS) 变化 (≥2点下降或NAS ≤3) 定义的MASH改善.
- 通过肝细胞膨胀和叶状炎症 (0或0-1,分别) 的特定分数来定义MASH分辨率.
- 通过≥1个阶段的减少来确定纤维化改善,确保MASH组件不会恶化.
主要成果:
- MASH改善:在48周内,NAS降低≥2点或NAS≤3,纤维化没有恶化.
- MASH解析:在48周,气球分数为0和炎症分数为0或1,纤维化没有恶化.
- 纤维化改善:在48周后≥1个阶段的减少,MASH组件没有恶化.
结论:
- 建立了MASH改善,解决和纤维化改善的清晰,可量化的定义.
- 这些定义为评估MASH疗法提供了标准化的终点.
- 持续的结果测量对于推动MASH研究和治疗至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
769
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
713
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
713
Glucose Transporters
27.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.8K
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Dipeptidyl Peptidase 4 Inhibitors
821
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
821
Glucose Absorption Into the Small Intestine
36.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
36.7K


